Pharming Group N.V. Sustainability Profile
Pharming Group N.V., a biopharmaceutical company headquartered in the Netherlands, is at the forefront of developing innovative therapies for rare diseases. Founded in 1988, Pharming has achieved significant milestones, including the successful launch of its flagship product, Ruconest, which is used to treat hereditary angioedema. With a strong focus on protein replacement therapies, Pharming operates primarily in Europe and North America, positioning itself as a leader in the biopharmaceutical industry. The company is dedicated to addressing unmet medical needs through its unique recombinant technology, which sets its products apart in the market. Notably, Pharming has garnered recognition for its commitment to research and development, solidifying its reputation as a key player in the field of rare disease treatment.
DitchCarbon Score
How does Pharming Group N.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharming Group N.V.'s score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharming Group N.V.'s reported carbon emissions
Pharming Group N.V., headquartered in the Netherlands, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges from the company. This lack of data suggests that Pharming Group N.V. may not have established formal commitments to reduce its carbon footprint or may not publicly disclose such information. In the context of the pharmaceutical industry, many companies are increasingly focusing on sustainability and climate action, often setting science-based targets to align with global climate goals. However, without specific emissions data or reduction initiatives, it is unclear how Pharming Group N.V. positions itself within this evolving landscape.
How Carbon Intensive is Pharming Group N.V.'s Industry?
How Carbon Intensive is Pharming Group N.V.'s Location?
Pharming Group N.V.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharming Group N.V. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
